Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD

December 23rd 2024

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD

December 18th 2024

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.

Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD

December 18th 2024

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS

December 16th 2024

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.

Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD

November 27th 2024

Hear Chandler Park, MD and Stephen Liu, MD, explore advancements in EGFR-mutated NSCLC treatment, including TKI strategies, emerging therapies prioritizing a patient-centric approach.

Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH

November 21st 2024

Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

November 14th 2024

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.

Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS

November 7th 2024

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

October 30th 2024

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

October 24th 2024

Hear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

October 16th 2024

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

October 7th 2024

Martin Dietrich, MD, PhD, discusses updated efficacy findings from the 18-month follow-up of the phase 2 VISION trial.

Revisit Every OncLive On Air Episode From September 2024

October 3rd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in September 2024.

Immunotherapy Advances Expand the SCLC Treatment Paradigm: With Chandler Park, MD, and Tejas Patil, MD

October 2nd 2024

Drs Park and Patil discuss the evolving small cell lung cancer treatment paradigm, focusing on PCI, immune checkpoint inhibitors, and recent study data.

Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting

September 19th 2024

Drs Thomas and Lukas discusses highlights in brain cancer research from the 2024 ASCO Annual Meeting.

Park and Patil Explore Advances in EGFR + NSCLC From ASCO 2024

September 18th 2024

In this episode, Drs Park and Patil discuss key updates from the 2024 ASCO Annual Meeting, including the significance of data from the phase 3 LAURA trial.

Camidge and Wilfong on Making A Difference Through a Career in Continuing Medical Education

September 12th 2024

D. Ross Camidge, MD, PhD, and Kadrin Wilfong, MD discuss Wilfong's passion for continuing medical education (CME) and how CME events and resources can make a difference in the care of patients with cancer.

Heme & Onc Fellow Board Review Tips 2024

September 9th 2024

Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams.

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

September 4th 2024

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.